Skip to main content

TIMM | Belgrade, Serbia | October 2017

By

TIMM Belgrade, Serbia | October 2017 Evaluate the Ability of CD101 to Prevent and Treat Candida albicans Biofilms and Explore its Temporal Effect by Time Lapse Photography PK/PD Target Characterization of the Novel Echinocandin CD101 Against Candida in a Neutropenic Mouse Model of Disseminated Candidiasis New Antifungal Drugs in the Pipeline- CD101 (Scientific Program Presentation)

Read More

IDWeek | San Diego, CA | October 2017

By

IDWeek San Diego, CA | October 2017 Evaluation of the Efficacy of CD101, a Novel Echinocandin, in the Treatment of Candida auris Infection Using a Murine Model of Disseminated Candidiasis In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against  C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model

Read More

ASM Microbe | New Orleans, LA | June 2017

By

ASM Microbe New Orleans, LA | June 2017 A Single-Dose, Subcutaneous (SC) Prophylaxis CD101 Administration Prevents Fungal Infection in Mouse Models of Candidiasis and Aspergillosis Real-World Use of Echinocandins in an Era of Increasing Antifungal Resistance

Read More

ECCMID | Vienna, Austria | April 2017

By

ECCMID Vienna, Austria | April 2017 Susceptibility of Recent Candida auris Isolates to the Novel Echinocandin CD101 and Comparator Antifungal Agents Prophylactic, Single-Dose, Subcutaneous (SC) Administration of CD101 Shows Robust Efficacy in Neutropenic Mouse Models of Candidiasis and Aspergillosis

Read More